CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for CIDP: modified immune protein enters human testing
Disease control Recruiting nowThis Phase 2 study is testing TAK-411, a specially modified immune globulin, in 36 adults with CIDP, an autoimmune disease that attacks nerve insulation and causes muscle weakness. The main goal is to see if TAK-411 improves physical function over 24 weeks compared to historical …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot for nerve disease could mean fewer infusions
Disease control Recruiting nowThis phase 3 trial is testing whether a new, more concentrated antibody treatment (TAK-881) works similarly to the current standard (HYQVIA) for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). About 59 participants who already receive antibody infusi…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
CIDP patients switching to HyQvia: what drives the choice?
Disease control Recruiting nowThis study follows 30 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will use questionnaires and medical records to understand why patients chose to switch, how satisfied they are, and how the treatment …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC